Nature’s Tiny Mystery
“The tiny structures had a complex but consistent barrel-shape morphology and measured 35 by 65 nanometers—much smaller than lysosomes.” What was it and why was it there? Read More
Bioengineering For Therapeutics
We prepare recombinant vaults by bio-engineering the major vault protein using the baculovirus expression system. We are able to load viral and bacterial antigens, like the gag-1 HIV envelope or larger peptides like CCL21 or NY-ESO-1. Read More
Novel Drug Discovery Approach
We have discovered how to package a wide variety of payloads (primarily peptides) into the vaults by exploiting a naturally occurring characteristic of the MVP called the interaction domain to induce a robust t-cell specific response. Read More
Vaults in Scientific Literature
Review published peer reviewed scientific articles about the human vault particles and their function, characteristics, and morphology. Read More
Vault Pharma in the News
Vault Pharma Announces Dr. James Mulé & Dr. Antoni Ribas to Join Scientific Advisory Board – Read More
Collaborations
Vault Pharma is engaged in collaborations in pharmaceutical, academic, and government sectors. We are actively seeking collaborators to enhance human dominion over the disease states of oncology, infectious diseases, and auto-immune disorders. Collaborate
Nature’s Elegant Design
Naturally occurring human vault particles are ubiquitous and present in every human cell and are the most abundant cytoplasmic protein particle in human cells, 10,000 plus particles per human cell. Evidence suggest that they function as an early alert signal to the immune system once a cell is damaged or lysed thereby releasing their human vault particles into the intracellular space where they are rapidly engulfed by antigen presenting cells, APCs. This makes vaults an ideal platform technology to introduce targeted substances to the immune system.
#platform
Continue The Tour
Dr. Leonard Rome Presents Vaults at TEDx
Latest News
Recent Posts / View All Posts
LOS ANGELES--(BUSINESS WIRE)--An emerging company developing biotechnology invented at UCLA is adapting their approach to address the novel coronavirus, with the goal of adding to the anti-COVID-19 arsenal that follows an initial vaccine. The company, Vault Pharma, is working with UCLA and other universities to advance a vaccine with the potential to treat the virus in addition to protecting against it. Vault Pharma was co-founded by Leonard H. Rome, distinguished professor of biological chemistry and…
ARDS has been identified as the leading cause of COVID-19-related fatalities; in preclinical studies, Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation, lessening inflammation, reducing edema and decreasing bacterial infection LOS ANGELES, April 15, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Addressing the finding that most fatalities from COVID-19 are caused by the nonreversible development of acute respiratory distress syndrome (ARDS), Multiverse Investment Fund I, LP, a private…
Finalists in Global Competition to Present to Members of Investment and Venture Capitalists Communities Los Angeles, CA: (PRWEB) June 15, 2017 -- Vault Pharma, an immunology-focused biotechnology company developing precision therapies for cancer, Women’s health, and infectious diseases, has been selected as a finalist and will present before an international panel of judges and investors on June 21, 2017, in San Diego at Start-Up Stadium at the BIO International Convention, the world's largest biotechnology event.…
